Back to Ebooks
MES for Pharma in 2030: Regulatory and Technical Trajectory
Continuous manufacturing, risk-based validation and patient-level traceability are redefining what a Manufacturing Execution System must deliver in regulated plants. This brief maps the standards and technical developments that will shape MES requirements through 2030, with practical criteria for evaluating your next system.
Learn about:
- •What an MES does, and doesn’t do, under the ISA-95 and ISA-88 reference models
- •The regulatory baseline: 21 CFR Part 11, EU GMP Annex 11, ALCOA+ and ICH Q13
- •Real-time release testing and PAT integration for continuous manufacturing
- •Computer Software Assurance (CSA) and what risk-based validation means for MES
- •DSCSA serialization, cloud and hybrid deployment, and AI-assisted quality review
- •Technical criteria to evaluate an MES for 2030 readiness
Download your eBook here
Check out our privacy policy
RAILES gives manufacturers a next-generation MES to optimise production, reduce waste, and drive continuous improvement.
✦ Trusted by industry leaders
